Stephen R.D. Johnston
Impact in
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
Papers in
- Oncology 106
- HER2/EGFR in Cancer Research 63
- Cancer Treatment and Pharmacology 23
- Cancer-related Molecular Pathways 17
- Lung Cancer Research Studies 10
-
- Advanced Breast Cancer Therapies 71
- Co-authors
- Mitch Dowsett (47 shared papers)Lesley‐Ann Martin (19 shared papers)Ian E. Smith (18 shared papers)Simone I. DETRE (12 shared papers)Alexandra F. Leary (7 shared papers)Masakazu Toi (11 shared papers)Xavier B. Pivot (5 shared papers)Lisa O’Rourke (7 shared papers)
- Journals
- Annals of Oncology (19 papers)Breast Cancer Research and Treatment (18 papers)Journal of Clinical Oncology (15 papers)Clinical Cancer Research (13 papers)Breast Cancer Research (10 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Stephen R.D. Johnston
204 papers receiving 13.3k citations
Stephen R.D. Johnston's Hit Papers
Peers
Comparison fields: 5 of 124
- Cancer Research 4.0k
- Oncology 6.5k
- Pulmonary and Respiratory Medicine 6.0k
- Genetics 919
- Genetics 2.2k
Countries citing papers authored by Stephen R.D. Johnston
This map shows the geographic impact of Stephen R.D. Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen R.D. Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen R.D. Johnston more than expected).
Fields of papers citing papers by Stephen R.D. Johnston
This network shows the impact of papers produced by Stephen R.D. Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen R.D. Johnston. The network helps show where Stephen R.D. Johnston may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephen R.D. Johnston, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 211 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer Hit paper breakdown → | 2009 | 838 |
| 2 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 Hit paper breakdown → | 2019 | 754 |
| 3 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Hit paper breakdown → | 2020 | 721 |
| 4 | Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2016 | 603 |
| 5 | MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer Hit paper breakdown → | 2019 | 510 |
| 6 | Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Hit paper breakdown → | 2016 | 495 |
| 7 | 2005 | 406 | |
| 8 | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 400 |
| 9 | 2017 | 336 | |
| 10 | Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer Hit paper breakdown → | 2019 | 315 |
| 11 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Hit paper breakdown → | 2021 | 273 |
| 12 | 2003 | 260 | |
| 13 | 2016 | 258 | |
| 14 | 2016 | 254 | |
| 15 | 2013 | 227 | |
| 16 | In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. | 1995 | 216 |
| 17 | 2020 | 198 | |
| 18 | 2008 | 185 | |
| 19 | 2010 | 184 | |
| 20 | 2018 | 179 |
About Stephen R.D. Johnston
Stephen R.D. Johnston is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics and Molecular Biology, having authored 211 papers that have together received 13.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (71 papers), HER2/EGFR in Cancer Research (63 papers), Estrogen and related hormone effects (50 papers), Breast Cancer Treatment Studies (41 papers), Cancer Treatment and Pharmacology (23 papers), Cancer-related Molecular Pathways (17 papers), PI3K/AKT/mTOR signaling in cancer (17 papers) and Lung Cancer Research Studies (10 papers). The work is most often cited by research in Cancer Research (4.0k citations), Oncology (6.5k citations), Pulmonary and Respiratory Medicine (6.0k citations), Genetics (919 citations) and Genetics (2.2k citations). Stephen R.D. Johnston has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Mitch Dowsett, Lesley‐Ann Martin, Ian E. Smith, Simone I. DETRE, Alexandra F. Leary, Masakazu Toi, Xavier B. Pivot, Lisa O’Rourke, Martin Frenzel and Julie Maltzman. Their work appears in journals such as Annals of Oncology, Breast Cancer Research and Treatment, Journal of Clinical Oncology, Clinical Cancer Research and Breast Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.